TY  - INPR
N1  - Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Y1  - 2020/10/16/
AV  - public
TI  - Respiratory trajectories in type 2 and non-ambulant 3 Spinal muscular atrophy in the iSMAC cohort study
A1  - Trucco, F
A1  - Ridout, D
A1  - Scoto, M
A1  - Coratti, G
A1  - Main, ML
A1  - Lofra, RM
A1  - Mayhew, AG
A1  - Montes, J
A1  - Pane, M
A1  - Sansone, V
A1  - Albamonte, E
A1  - D'Amico, A
A1  - Bertini, E
A1  - Messina, S
A1  - Bruno, C
A1  - Parasuraman, D
A1  - Childs, A-M
A1  - Gowda, V
A1  - Willis, T
A1  - Ong, M
A1  - Marini-Bettolo, C
A1  - De Vivo, DC
A1  - Darras, BT
A1  - Day, J
A1  - Kichula, EA
A1  - Mayer, OH
A1  - Navas Nazario, AA
A1  - Finkel, RS
A1  - Mercuri, E
A1  - Muntoni, F
A1  - International SMA consortium (iSMAc)
KW  - Natural history studies (prognosis)
JF  - Neurology
UR  - https://doi.org/10.1212/WNL.0000000000011051
N2  - OBJECTIVE: To describe the respiratory trajectories and their correlation with motor function in an international paediatric cohort of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA). METHODS: Eight-year retrospective observational study of patients in the iSMAc natural history study. We retrieved anthropometrics, forced vital capacity (FVC) absolute, FVC% predicted (FVC%P.), Non-Invasive ventilation (NIV) requirement. Hammersmith functional motor scale (HFMS) and Revised performance of upper limb (RULM) were correlated with respiratory function. We excluded patients in interventional clinical trials and on Nusinersen commercial therapy. RESULTS: There were 437 patients with SMA: 348 type 2, 89 non-ambulant type 3. Mean age at first visit was 6.9(±4.4) and 11.1(±4) years. In SMA type 2 FVC%P declined by 4.2%/year from 5 to 13 years, followed by a slower decline (1.0%/year). In type 3 FVC%P declined by 6.3%/year between 8 and 13 years, followed by a slower decline (0.9%/year). 39% SMA type 2 and 9% type 3 required NIV at median age 5.0(1.8-16.6) and 15.1(13.8-16.3) years. 84% SMA type 2 and 80% type 3 had scoliosis, 54% and 46% required surgery, which did not significantly affect respiratory decline. FVC%P positively correlated with HFMS and RULM in both subtypes. CONCLUSIONS: In SMA type 2 and non-ambulant type 3 lung function declines differently, with a common levelling after age 13 years. Lung and motor function correlated in both subtypes. Our data further defines the milder SMA phenotypes and provides novel information to benchmark the long-term efficacy of new treatments for SMA.
ID  - discovery10113291
ER  -